Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.36 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15473014 | 0.81 | OTC (0.40) | OTCCA2CA9 | |
| SCHEMBL23662885 | 0.81 | CA2 (0.35) | CA2CA9 | |
| SCHEMBL15469217 | 0.80 | CASR (0.37) | OTCGFPT1 | |
| SCHEMBL24610028 | 0.79 | OTC (0.44) | OTC | |
| SCHEMBL15469244 | 0.79 | OTC (0.44) | OTC | |
| SCHEMBL16447237 | 0.74 | NOD1 (0.49) | OTC | |
| SCHEMBL14285708 | 0.74 | CA2 (0.36) | CA2CA9 | |
| SCHEMBL15469218 | 0.73 | GFPT1 (0.36) | OTCGFPT1 | |
| SCHEMBL20834979 | 0.73 | OTC (0.44) | OTCCA2CA9 | |
| SCHEMBL16447372 | 0.72 | GFPT1 (0.34) | GFPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207859-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | SUTRO BIOPHARMA, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207859-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | CD74, CD99, CD2 | OTC 3953/4885GFPT1 4446/4885CA2 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.